1182 related articles for article (PubMed ID: 17052967)
21. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
[TBL] [Abstract][Full Text] [Related]
22. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
23. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
24. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
Zeller W; Gutensohn K; Stockschläder M; Dierlamm J; Kröger N; Koehne G; Hummel K; Kabisch H; Weh HJ; Kühnl P; Hossfeld DK; Zander AR
Bone Marrow Transplant; 1996 May; 17(5):709-13. PubMed ID: 8733686
[TBL] [Abstract][Full Text] [Related]
25. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
[TBL] [Abstract][Full Text] [Related]
26. Detection and quantification of functionally defined hematopoietic progenitor cells and tissue specific mRNA within the peripheral blood of myeloma patients after administration of granulocyte colony-stimulating factor and erythropoietin.
Grassinger J; Mueller G; Hart C; Nilsson SK; Haylock DN; Andreesen R; Hennemann B
Eur J Haematol; 2008 Jan; 80(1):20-30. PubMed ID: 18028434
[TBL] [Abstract][Full Text] [Related]
27. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
28. Long-term cultures to evaluate engraftment potential of CD34+ cells from peripheral blood after mobilization by chemotherapy with and without GM-CSF.
Benboubker L; Domenech J; Linassier C; Desbois I; Delain M; Lamagnere JP; Colombat P; Binet C
Exp Hematol; 1995 Dec; 23(14):1568-73. PubMed ID: 8542948
[TBL] [Abstract][Full Text] [Related]
29. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
30. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
31. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease.
Gaia S; Smedile A; Omedè P; Olivero A; Sanavio F; Balzola F; Ottobrelli A; Abate ML; Marzano A; Rizzetto M; Tarella C
J Hepatol; 2006 Jul; 45(1):13-9. PubMed ID: 16635534
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors.
Shier LR; Schultz KR; Imren S; Regan J; Issekutz A; Sadek I; Gilman A; Luo Z; Panzarella T; Eaves CJ; Couban S
Biol Blood Marrow Transplant; 2004 Sep; 10(9):624-34. PubMed ID: 15319774
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
[TBL] [Abstract][Full Text] [Related]
35. Expression of adhesion molecules on CD34(+) cells in peripheral blood of non-hodgkin's lymphoma patients mobilized with different growth factors.
Gazitt Y; Shaughnessy P; Liu Q
Stem Cells; 2001; 19(2):134-43. PubMed ID: 11239168
[TBL] [Abstract][Full Text] [Related]
36. [The follow-up of the mobilization of circulating hematopoietic progenitor cells by granulocyte growth factor (G-CSF) using flow cytometry].
De Arriba F; Ortuño F; Rivera J; Heras I; Funes C; Moraleda JM; Vicente V
Med Clin (Barc); 1995 Jan; 104(2):41-4. PubMed ID: 7532770
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial.
Ripa RS; Haack-Sørensen M; Wang Y; Jørgensen E; Mortensen S; Bindslev L; Friis T; Kastrup J
Circulation; 2007 Sep; 116(11 Suppl):I24-30. PubMed ID: 17846310
[TBL] [Abstract][Full Text] [Related]
38. GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression.
Watanabe T; Dave B; Heimann DG; Lethaby E; Kessinger A; Talmadge JE
Bone Marrow Transplant; 1997 Jun; 19(12):1175-81. PubMed ID: 9208110
[TBL] [Abstract][Full Text] [Related]
39. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
[TBL] [Abstract][Full Text] [Related]
40. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.
Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L
Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
